Highlights,Mineralys Therapeutics' stock opened at $10.15, reflecting recent market adjustments.,Executive transactions ...

Q4 2024 Earnings Call Transcript February 12, 2025 Mineralys Therapeutics, Inc. beats earnings expectations. Reported EPS is ...

In a report released today, Richard Law CFA from Goldman Sachs maintained a Buy rating on Mineralys Therapeutics, Inc. (MLYS – Research ...

Jon Congleton; Chief Executive Officer, Director; Mineralys Therapeutics Inc. David Rodman; Chief Medical Officer ...

CEO Jon Congleton highlighted the company's focus on advancing its pivotal trials for lorundrostat, targeting dysregulated aldosterone in patients with uncontrolled and resistant hypertension. He ...

The co-extrusion of this demonstration coupon sample represents a key fabrication milestone under Lightbridge's Strategic ...

This past year was important for the development of lorundrostat, and the entire Mineralys team contributed to the execution of our clinical ...

Anticipate topline data from pivotal Advance-HTN trial in March 2025 and pivotal Phase 3 Launch-HTN trial in mid first half of 2025 – – Completed enrollment in Explore-CKD Phase 2 trial and anticipate ...

SunCar Technology Group Inc. SDA fell 18.3% to $6.90 in pre-market trading after the company reported the pricing of $50 ...

Mineralys Therapeutics, Inc. (NASDAQ: MLYS) has announced the completion of enrollment in the explore-CKD phase 2 trial for ...

RADNOR, Pa. - Mineralys Therapeutics , Inc. (NASDAQ:MLYS), a biopharmaceutical company specializing in the development of treatments for cardiovascular and kidney diseases, has announced the ...

Shares of Twilio Inc. TWLO rose sharply in today's pre-market trading after the company provided preliminary financial results for the fourth quarter. After the market close on Thursday, Twilio ...